TGTX241227C54000
- 0.00
- 0.000.00%
TG Therapeutics Newsroom
Jefferies Sticks to Their Buy Rating for TG Therapeutics (TGTX)
TG Therapeutics Is Maintained at Overweight by JP Morgan
TG Therapeutics Analyst Ratings
J.P. Morgan Maintains TG Therapeutics(TGTX.US) With Buy Rating, Raises Target Price to $43
TG Therapeutics Price Target Raised to $55.00/Share From $49.00 by HC Wainwright & Co.
TG Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Goldman Sachs Maintains Neutral on TG Therapeutics, Raises Price Target to $22
A Quick Look at Today's Ratings for TG Therapeutics(TGTX.US), With a Forecast Between $38 to $55
TG Therapeutics: Promising Growth Trajectory and Blockbuster Potential Justify Buy Rating
TD Cowen Initiates TG Therapeutics(TGTX.US) With Buy Rating, Announces Target Price $50
TD Cowen Initiates TG Therapeutics at Buy With $50 Price Target
TG Therapeutics Analyst Ratings
B.Riley Financial Maintains TG Therapeutics(TGTX.US) With Buy Rating, Raises Target Price to $38
H.C. Wainwright Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $49
Analysts' Top Healthcare Picks: TG Therapeutics (TGTX), Boston Scientific (BSX)
TG Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $49 Price Target
Goldman Sachs Maintains Neutral on TG Therapeutics, Raises Price Target to $20
Goldman Sachs Maintains TG Therapeutics(TGTX.US) With Hold Rating, Raises Target Price to $20
Maintaining Hold on TG Therapeutics Amidst Positive Performance and Ongoing Uncertainties